{
  "docId": "019de076-8cfe-74f8-8267-71bfaaa75a6b",
  "docSlug": "6f650cb16e144ff2cbcc39c10e5d03e1",
  "documentTitle": "23andMe | Investor Presentation Deck | 39 slides",
  "authorId": "23andme",
  "authorName": "23andMe",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 28,
  "pageCount": 39,
  "prevPage": 27,
  "nextPage": 29,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 27,
  "notes": "The chart demonstrates superior efficacy of 23ME-00610 over anti-PD1 in stimulating IFNy across multiple cancer types.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-8cfe-74f8-8267-71bfaaa75a6b/28",
  "deckHref": "/decks/019de076-8cfe-74f8-8267-71bfaaa75a6b",
  "deckJsonHref": "/decks/019de076-8cfe-74f8-8267-71bfaaa75a6b.json",
  "deckAnchorHref": "/decks/019de076-8cfe-74f8-8267-71bfaaa75a6b#slide-28",
  "components": [
    {
      "bbox": {
        "h": 0.45,
        "w": 0.7,
        "x": 0.15,
        "y": 0.33
      },
      "kind": "chart",
      "text": "IFNy fold change relative to isotype across 9 cancer types",
      "attrs": null,
      "subkind": "bar-grouped",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2a31a40f-a97a-4ba2-84c0-c713698e96b5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.65,
        "x": 0.1,
        "y": 0.89
      },
      "kind": "disclaimer",
      "text": "PBMCs from each respective patient were incubated with 100 nM of 23ME-00610, anti-PD-1, or isotype control. Cells were stimulated with SEB. IFNy levels were determined by enzyme-linked immunosorbent assay. Mean biologic triplicates were normalized to isotype control. * p-value<=0.05 compared to control",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "47bcc7e2-5b28-4b4b-9505-2a4766b4bc8a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.52,
        "x": 0.24,
        "y": 0.19
      },
      "kind": "paragraph",
      "text": "Blocking the CD200R1 pathway enhanced IFNy production from SEB-stimulated PBMCs compared to isotype control and anti-PD1 in the majority of samples tested",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8c3b8ee2-8fa3-4684-b836-b9ab2843d1ad",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.15,
        "x": 0.73,
        "y": 0.73
      },
      "kind": "source-note",
      "text": "PBMC, peripheral blood mononuclear cell; PD-1, programmed death-1; SEB, staphylococcal enterotoxin B.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fde7b3d2-29e0-4516-9292-308b8d25a641",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.66,
        "x": 0.17,
        "y": 0.05
      },
      "kind": "title",
      "text": "610 Differentiation: Inhibition of CD200R1 Has the Potential to Address Resistance to Anti-PD1 Therapies",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "902af5ea-bee9-491d-a2b3-0a7300979627",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 39,
      "from": 9,
      "beatId": "93eec936-fceb-4bb2-ab9b-6265df978407",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "Slides 9-39 present 23andMe's solution, including their therapeutic pipeline and approach",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}